[
DLCBL radiomics
PET lymphoma
PET radiomics
radiomic PET biomarker
Journal
Hematological oncology
ISSN: 1099-1069
Titre abrégé: Hematol Oncol
Pays: England
ID NLM: 8307268
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
revised:
13
03
2023
received:
26
08
2022
accepted:
21
04
2023
pubmed:
20
5
2023
medline:
20
5
2023
entrez:
20
5
2023
Statut:
ppublish
Résumé
To evaluate the association between radiomic features (RFs) extracted from
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
674-682Informations de copyright
© 2023 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.
Références
Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116(19):3724-3734. https://doi.org/10.1182/blood-2010-05-282632
Harrysson S, Eloranta S, Ekberg S, et al. Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden. Blood Cancer J. 2021;11(1):9. https://doi.org/10.1038/s41408-020-00403-1
International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993). A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med, 329(14), 987-994. https://doi.org/10.1056/NEJM199309303291402
Poeschel V, Held G, Ziepert M, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet (London, Engl. 2019;394(10216):2271-2281. https://doi.org/10.1016/S0140-6736(19)33008-9
Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503-511. https://doi.org/10.1038/35000501
Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679-690. https://doi.org/10.1038/s41591-018-0016-8
Reddy A, Zhang J, Davis NS, et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017;171(2):481-494. https://doi.org/10.1016/j.cell.2017.09.027
Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Am Soc Clin Oncol. 2012;30(28):3460-3467. https://doi.org/10.1200/JCO.2011.41.4342
Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Am Soc Clin Oncol. 2012;30(28):3452-3459. https://doi.org/10.1200/JCO.2011.41.0985
Zhang J, Grubor V, Love CL, et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc. Natl. Acad. Sci. U.S.A. 2013;110(4):1398-1403. https://doi.org/10.1073/pnas.1205299110
Voltin CA, Mettler J, Grosse J, et al. FDG-PET imaging for hodgkin and diffuse large B-cell lymphoma-an updated overview. Cancers. 2020;12(3):601. https://doi.org/10.3390/cancers12030601
Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol official. 2014;32(27):3048-3058. https://doi.org/10.1200/JCO.2013.53.5229
Mikhaeel NG, Smith D, Dunn JT, et al. Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imag. 2016;43(7):1209-1219. https://doi.org/10.1007/s00259-016-3315-7
Ceriani L, Martelli M, Zinzani PL, et al. Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. Blood. 2015;126(8):950-956. https://doi.org/10.1182/blood-2014-12-616474
Kim TM, Paeng JC, Chun IK, et al. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma. Cancer. 2013;119(6):1195-1202. https://doi.org/10.1002/cncr.27855
Cottereau AS, Lanic H, Mareschal S, et al. Molecular profile and FDG-PET/CT total metabolic tumor volume improve risk classification at diagnosis for patients with diffuse large B-cell lymphoma.J Am Assoc Cancer Res. 2016;22(15):3801-3809. https://doi.org/10.1158/1078-0432.CCR-15-2825
Parvez A, Tau N, Hussey D, Maganti M, Metser U. 18F-FDG PET/CT metabolic tumor parameters and radiomics features in aggressive non-Hodgkin's lymphoma as predictors of treatment outcome and survival. Ann Nucl Med. 2018;32(6):410-416. https://doi.org/10.1007/s12149-018-1260-1
Eertink JJ, van de Brug T, Wiegers SE, et al. 18F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imag. 2022;49(3):932-942. https://doi.org/10.1007/s00259-021-05480-3
Cottereau AS, Nioche C, Dirand AS, et al. 18F-FDG PET dissemination features in diffuse large B-cell lymphoma are predictive of outcome. J Nucl Med official Publ Soc Nucl Med. 2020;61(1):40-45. https://doi.org/10.2967/jnumed.119.229450
Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imag. 2015;42(2):328-354. https://doi.org/10.1007/s00259-014-2961-x
Nioche C, Orlhac F, Boughdad S, et al. LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res. 2018;78(16):4786-4789. https://doi.org/10.1158/0008-5472.CAN-18-0125
Botta F, Ferrari M, Raimondi S, et al. The impact of segmentation method and target lesion selection on radiomic analysis of 18F-FDG PET images in diffuse large B-cell lymphoma. Appl Sci. 2022;12(19):9678. https://doi.org/10.3390/app12199678
Barrington SF, Meignan M. Time to prepare for risk adaptation in lymphoma by standardizing measurement of metabolic tumor burden. J Nucl Med official Publ. Soc Nucl Med. 2019;60(8):1096-1102. https://doi.org/10.2967/jnumed.119.227249
Harrel FE, Jr, Lee KL, Mark DB. Tutorial in biostatistics: multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Statistics Med. 1996;15(4):361-387. https://doi.org/10.1002/(sici)1097-0258(19960229)15:4<361::aid-sim168>3.0.co;2-4
Pencina MJ, D’Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Statistics Med. 2004;23(13):2109-2123. https://doi.org/10.1002/sim.1802
Jiang C, Li A, Teng Y, et al. Optimal PET-based radiomic signature construction based on the cross-combination method for predicting the survival of patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imag. 2022;49(8):2902-2916. https://doi.org/10.1007/s00259-022-05717-9
Wang H, Zhao S, Li L, Rong T. Development and validation of an 18F-FDG PET radiomic model for prognosis prediction in patients with nasal-type extranodal natural killer/T cell lymphoma. Eur Radiol. 2020;30(10):5578-5587. https://doi.org/10.1007/s00330-020-06943-1
Xu H, Abdallah N, Marion J.-M, et al. Radiomics prognostic analysis of PET/CT images in a multicenter head and neck cancer cohort: investigating ComBat strategies, sub-volume characterization, and automatic segmentation. Eur J Nucl Med Mol Imag. 2023;50(6):1720-1734. https://doi.org/10.1007/s00259-023-06118-2
Xie M, Zhai W, Cheng S, Zhang H, Xie Y, He W. Predictive value of F-18 FDG PET/CT quantization parameters for progression-free survival in patients with diffuse large B-cell lymphoma. Hematology (N Y). 2016;21(2):99-105. https://doi.org/10.1179/1607845415Y.0000000033
Sasanelli M, Meignan M, Haioun C, et al. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imag. 2014;41(11):2017-2022. https://doi.org/10.1007/s00259-014-2822-7
Zhou M, Chen Y, Huang H, Zhou X, Liu J, Huang G. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma. Oncotarget. 2016;7(50):83544-83553. https://doi.org/10.18632/oncotarget.13180
Jin X, Wei M, Wang S, et al. Detecting fibroblast activation proteins in lymphoma using 68Ga-FAPI PET/CT. J Nucl Med official Publ Soc Nucl Med. 2022;63(2):212-217. https://doi.org/10.2967/jnumed.121.262134
Staudt LM, Dave S. The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol. 2005;87:163-208. https://doi.org/10.1016/S0065-2776(05)87005-1
Aide N, Fruchart C, Nganoa C, Gac AC, Lasnon C. Baseline 18F-FDG PET radiomic features as predictors of 2-year event-free survival in diffuse large B cell lymphomas treated with immunochemotherapy. Eur Radiol. 2020;30(8):4623-4632. https://doi.org/10.1007/s00330-020-06815-8
Lue KH, Wu YF, Lin HH, et al. Prognostic value of baseline radiomic features of 18F-FDG PET in patients with diffuse large B-cell lymphoma. Diagnostics. 2020;11(1):36. https://doi.org/10.3390/diagnostics11010036
Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol official J Eur Soc Med Oncol. 2015;26((Suppl 5)):v116-v125. https://doi.org/10.1093/annonc/mdv304
Cancer Stat Facts: NHL - Diffuse Large B-Cell Lymphoma (DLBCL) [Internet]. 2018 [cited 2022 Apr 21]. https://seer.cancer.gov/statfacts/html/dlbcl.html/
Steyerberg EW. Validation in prediction research: the waste by data splitting. J Clin Epidemiol. 2018;103:131-133. https://doi.org/10.1016/j.jclinepi.2018.07.010
Zwanenburg A. Radiomics in nuclear medicine: robustness, reproducibility, standardization, and how to avoid data analysis traps and replication crisis. Eur J Nucl Med Mol Imag. 2019;46(13):2638-2655. https://doi.org/10.1007/s00259-019-04391-8
Eertink J, Zwezerijnen G, Cysouw M, et al. Comparing lesion and feature selections to predict progression in newly diagnosed DLBCL patients with FDG PET/CT radiomics features. Eur J Nucl Med Mol Imag. 2022;49(13):4642-4651. https://doi.org/10.1007/s00259-022-05916-4